Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pediatric advisory committee considers heartburn drugs

This article was originally published in The Tan Sheet

Executive Summary

FDA's Pediatric Advisory Committee will meet June 21 in Bethesda, Md., to discuss pediatric safety reviews for several drugs, including proton pump inhibitors Prevacid (lansoprazole) and Prilosec (omeprazole), according to a May 11 Federal Register notice. The notice does not specify if the drugs could be available to children in the future, but currently both products are recommended for patients 18 years and older. Comments are due June 7
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS104121

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel